The Full Wiki

More info on Renzapride

Renzapride: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Renzapride
Systematic (IUPAC) name
4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]non-4-yl]-5-chloro-2-methoxybenzamide
Identifiers
CAS number 109872-41-5
ATC code none
PubChem 3086547
Chemical data
Formula C 16H22ClN3O2  
Mol. mass 323.818 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist.[1][2] It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.[1]

Renzapride was being developed by Alizyme plc of the United Kingdom.

Clinical trials

Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.

As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.[3]

References

  1. ^ a b Meyers NL, Hickling RI. (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.". Drugs R D. 9 (1): 37–63. PMID 18095752.  
  2. ^ Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904
  3. ^ Alizyme plc (23 April 2008). "Results from Renzapride". Press release. http://www.alizyme.com/alizyme/media/press/show.jsp?ref=128. Retrieved 7 May 2009.  
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message